Mirapex在1997年获得美国食品药物管理局 (FDA)核准上市，是治疗帕金森氏症广受欢迎的新药，它借由抑制大脑多巴胺的活动，改善患者颤抖及动作迟缓症状，去年列为此疾用药销量榜首，在美国一年市值2亿美元。

MIRAPEX ER prescription and dosage sizes information for physicians and healthcare professionals. Pharmacology, adverse reactions, warnings and side effects.

FDA also evaluated two epidemiologic studies that suggested an increased risk of new onset of heart failure with Mirapex use.1,2 However, study limitations make it difficult to determine whether ...

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily Mirapex ER® (pramipexole dihydrochloride) extended-release ...

For full MIRAPEX ER or MIRAPEX prescribing information, please contact Boehringer Ingelheim's Drug Information Unit at 1-800-542-6257. Boehringer Ingelheim Pharmaceuticals, Inc.

Mirapex’s labeling said it is indicated for treating moderate-to-severe primary restless leg syndrome (RLS). The labeling lists warnings, including falling asleep during activities of daily living, ...

But Mirapex got some free publicity riding on the coattails of the two RLS studies. “It was just a coincidence,” Kate O’Connor, Boehringer Ingelheim associate director, communications & PR, said about ...

Barr filed its Abbreviated New Drug Application (ANDA) for generic MirapexTablets, 0.25mg containing a paragraph IV certification with the FDA in May2005 and in June 2005 amended its application ...

Reimbursement for Parkinson's Disease Therapies is Generally Not Restricted in Any of the EU5 Countries, According to a New Report from Decision ResourcesBURLINGTON, Mass., Nov. 30, 2010 /PRNewswire/ ...